Market and Product Forecasts: Melanoma - Yervoy will continue to dominate as new approvals struggle to compete
NEW YORK, Nov. 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Market and Product Forecasts: Melanoma – Yervoy will continue to dominate as new approvals struggle to competehttp://www.reportlinker.com/p01037156/Market-and-Product-Forecasts-Melanoma-–-Yervoy-will-continue-to-dominate-as-new-approvals-struggle-to-compete.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
•Catalyst•Summary
EXECUTIVE SUMMARY•Strategic scoping and focus•Datamonitor key findings
MARKET DEFINITION •Market definition for melanoma
•Forecast methodology and assumptions - Methodology flow
- Patent expiries
- New product launches
•Additional forecast methodology
MARKET
OVERVIEW
AND CONTEXT•Melanoma therapies included in this report
•Current and future market dynamics overview - The branded melanoma market will experience a dramatic increase in sales over the forecast period
- Market entry of new drugs will dramatically increase the value of the branded melanoma market
- The commercial value of pipeline therapies will not surpass the total value of current marketed therapies
- New product launches will mostly impact the metastatic melanoma setting
- The US will remain the most lucrative market over the forecast period
- The overall value of branded melanoma therapies will increase across the five major EU markets
PRODUCT FORECASTS•Molecule dynamics - Yervoy will continue to dominate the melanoma market over the forecast period
•Yervoy (ipilimumab; Bristol-Myers Squibb) - Forecast assumptions
- Yervoy forecast 2012–21
•Zelboraf (vemurafenib; Roche/Daiichi Sankyo) - Forecast assumptions - Zelboraf forecast 2012–21
•Abraxane (albumin-bound paclitaxel; Celgene) - Forecast assumptions
- Abraxane forecast 2012–21
•Allovectin-7 (velimogene aliplasmid; Vical) - Forecast assumptions - Allovectin-7 forecast 2012–21
•Dabrafenib (GSK-2118436; GlaxoSmithKline) - Forecast assumptions
- Dabrafenib forecast 2012–21
•MAGE-A3 ASCI (astuprotimut-r; GlaxoSmithKline) - Forecast assumptions - MAGE-A3 ASCI forecast 2012–21
•OncoVEX GM-CSF (talimogene laherparepvec; Amgen) - Forecast assumptions
- OncoVEX forecast 2012–21
•POL-103A (Polynoma/CK Life Sciences) - Forecast assumptions - POL-103A forecast 2012–21
•Trametinib (GSK-1120212; GlaxoSmithKline) - Forecast assumptions
- Trametinib forecast 2012–21
BIBLIOGRAPHY•Journal papers•Websites
APPENDIX•Forecast methodology - Volume and value forecast methodology- Price and compliance assumptions
TABLES•Table: Summary of therapeutic classes in melanoma by ATC code, 2012•Table: Patent expiry dates for key marketed brands in melanoma, 2012•Table: Estimated launch dates for key late-stage pipeline products in melanoma, 2012–21•Table: Drugs included in melanoma market and product forecasts, 2012–21•Table: Melanoma drug sales in the US and five major EU markets ($m), 2012–21•Table: Melanoma drug sales in the US ($m), 2012–21•Table: Melanoma molecule sales in the five major EU markets ($m), 2012–21•Table: Key melanoma drug sales in the US and five major EU markets, 2012 and 2021•Table: Yervoy sales, by country ($m), 2012–21•Table: Yervoy patients, by country, 2012–21•Table: Zelboraf sales, by country ($m), 2012–21•Table: Zelboraf patients, by country, 2012–21•Table: Abraxane sales, by country ($m), 2012–21•Table: Abraxane patients, by country, 2012–21•Table: Allovectin-7 sales, by country ($m), 2012–21•Table: Allovectin-7 patients, by country, 2012–21•Table: Dabrafenib sales, by country ($m), 2012–21•Table: Dabrafenib patients, by country, 2012–21•Table: MAGE-A3 ASCI sales, by country ($m), 2012–21•Table: MAGE-A3 ASCI patients, by country, 2012–21•Table: OncoVEX GM-CSF sales, by country ($m), 2012–21•Table: OncoVEX GM-CSF patients, by country, 2012–21•Table: POL-103A sales, by country ($m), 2012–21•Table: POL-103A patients, by country, 2012–21•Table: Trametinib sales, by country ($m), 2012–21•Table: Trametinib patients, by country, 2012–21•Table: Price sources and calculations, by country, 2012•Table: Exchange rates used for calculating prices, 2012
FIGURES•Figure: Patient-based forecast methodology for melanoma, 2012•Figure: Melanoma market forecast across the US and five major EU markets, by country ($m), 2012–21•Figure: Melanoma sales in the US and five major EU markets, by class ($m), 2012–21•Figure: Estimated approval/launch dates of key melanoma therapies, 2012–21•Figure: Branded melanoma market value in the US, by drug class ($m), 2012–21•Figure: Branded melanoma market value in the five major EU markets, by drug class ($m), 2012–21•Figure: Key branded melanoma drug sales, 2012–21•Figure: Yervoy sales, by country ($m), 2012–21•Figure: Zelboraf sales, by country ($m), 2012–21•Figure: Abraxane sales, by country ($m), 2012–21•Figure: Allovectin-7 sales, by country ($m), 2012–21•Figure: Dabrafenib sales, by country ($m), 2012–21•Figure: MAGE-A3 ASCI sales, by country ($m), 2012–21•Figure: OncoVEX GM-CSF sales, by country ($m), 2012–21•Figure: POL-103A sales, by country ($m), 2012–21•Figure: Trametinib sales, by country ($m), 2012–21
Companies MentionedTo order this report:Pathology Industry: Market and Product Forecasts: Melanoma – Yervoy will continue to dominate as new approvals struggle to compete
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article